TrialClinical and experimental immunology2018
Clinical pharmacology of alemtuzumab, an anti-CD52 immunomodulator, in multiple sclerosis.
Z Li et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
40 papers cite it
this paperpooled ittrialcites it